Yazar "Tobu, M" seçeneğine göre listele
Listeleniyor 1 - 11 / 11
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Blood levels of nitric oxide and its relevance to C-reactive protein, CD 40L, TF and TNF? in malignancy associated hypercoagulable state.: Pathologic implications.(Amer Soc Hematology, 2003) Fareed, D; Bick, R; Bacher, P; Iqbal, O; Tobu, M; Hoppensteadt, D; Demir, A[Abstract Not Available]Öğe Clinical and laboratory validation of the 2nd International Standard of low molecular weight heparin (IS 2003-01/608) in the anti-Xa. Anti-LIA heptest and prothrombinase induced clotting (PiCT) tests(Amer Soc Hematology, 2005) Hoppensteadt, D; Jeske, W; Fareed, D; Baltasar, F; Walenga, JM; Tobu, M; Demir, M[Abstract Not Available]Öğe Comparative study on the anticoagulant effects of low molecular weight heparins as measured by whole blood ACT, anti-Xa and a newly developed prothrombinase induced clotting time (PiCT) assay(Amer Soc Hematology, 2005) Hoppensteadt, D; Tobu, M; Wahi, R; Iqbal, O; Walenga, JM; Demir, M; Baltasar, F[Abstract Not Available]Öğe Frequency of anti-erythropoietin antibodies in patients with end stage renal disease treated with recombinant erythropoietin(Amer Soc Hematology, 2005) Hoppensteadt, D; Tobu, M; Fareed, D; Iqbal, O; Baltasar, F; Patel, C; Bansal, V[Abstract Not Available]Öğe Hyperhomocysteinemia in cancer patients with thrombosis is independent of methylene tetrahydrofolate reductase gene mutation.(Amer Soc Hematology, 2004) Fareed, J; Tobu, M; Hoppensteadt, DA; Cunanan, J; Iqbal, O; Demir, M; Deitcher, S[Abstract Not Available]Öğe Prevalence and pathogenic role of anti-EPO antibodies in patients treated with recombinant erythropoietin(Amer Assoc Clinical Chemistry, 2004) Hoppensteadt, DA; Tobu, M; Chatha, M; Bansal, V; Moghaddam, M; Saxena, R; Ahmad, S[Abstract Not Available]Öğe Prevalence and pathogenic role of anti-EPO antibodies in patients treated with recombinant erythropoietin.(Amer Soc Hematology, 2003) Tobu, M; Hoppensteadt, DA; Chatha, M; Bansal, V; Moghaddam, M; Sarfraz, A; Demir, M[Abstract Not Available]Öğe Role of PAI-1 and TAFI in the mediation of fibrinolytic deficit in cancer patients.(Amer Soc Clinical Oncology, 2004) Florian-Kujawski, MR; Hoppensteadt, D; Iqbal, O; Demir, M; Tobu, M; Fareed, D; Fareed, J[Abstract Not Available]Öğe Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization(Blackwell Futura Publishing, Inc, 2005) Iqbal, O; Tobu, M; Aziz, S; Gerdisch, M; Da Valle, M; Demir, M; Hoppensteadt, DARefludan (lepirudin-rDNA for injection) is the first direct thrombin inhibitor approved by the United States FDA for anticoagulation to patients with heparin-induced thrombocytopenia (HIT). It was monitored by ecarin clotting time (ECT) assay in patients with HIT. Case histories and clotting parameters for three patients undergoing off-pump coronary artery revascularization procedure are discussed. The first patient received r-hirudin at a dose of 0.2 mg/kg intravenous (IV) bolus followed by 0.15 mg/kg/hour infusion. The second patient received 0.4 mg/kg IV bolus followed by infusion of 0.15 mg/kg/hour infusion. The third patient with renal failure received 0.2 mg/kg IV bolus followed by an infusion of 0.02 mg/kg/hour. Blood samples were drawn at baseline, 5 minutes post bolus and every 15 minutes during the coronary artery revascularization procedure. ECT was performed immediately on the citrated whole blood samples using the ECT cards in conjunction with the point-of-care, the thrombolytic assessment system (TAS) Analyzer (Pharmanetics, Raleigh, NC). The plasma samples were then analyzed for APTT and liquid ECT assay performed on a kinetic centrifugal analyzer (ACL 300 Plus). The ECT by cards was ideally maintained above 600 seconds during the surgical procedure. Additional boluses of Refludan were given as and when necessary (ECT < 600 sec) in order to maintain adequate anticoagulation. The calculated circulating concentrations of Refludan, following a bolus adminstration, based on the ECT cards, liquid ECT and APTT were 3.20 +/- 1.3, 3.51 +/- 1.35 and 2.02 +/- 1.19 mug/mL, respectively.Öğe Upregulation of monocyte chemotactic protein-1 and CD40 ligand in cancer and its modulation by a LMWH enoxaparin: Observations from the Oncenox study.(Amer Soc Hematology, 2003) Fareed, J; Hoppensteadt, D; Iqbal, O; Tobu, M; Demir, A; Cort, S; Deitcher, SR[Abstract Not Available]Öğe Upregulation of monocyte chemotactic protein-1 and CD40 ligand in cancer patients and their modulation by subcutaneous enoxaparin-results from the ONCENOX study(Amer Soc Clinical Oncology, 2004) Iqbal, O; Tobu, M; Demir, MA; Hoppensteadt, D; Fareed, J; Cort, S; Deitcher, S[Abstract Not Available]
